Human Metabolome Technologies, Inc. (TYO:6090)
559.00
0.00 (0.00%)
Nov 18, 2026, 9:00 AM JST
TYO:6090 Revenue
Human Metabolome Technologies had revenue of 253.00M JPY in the quarter ending September 30, 2026, with 31.77% growth. This brings the company's total for the last twelve months to 1.48B, up 7.94% year-over-year. In the fiscal year ending June 30, 2026, Human Metabolome Technologies had annual revenue of 1.42B, down -2.34%. That makes Human Metabolome Technologies the 37,745th largest company in the world by revenue and 3,733rd in Japan.
Revenue (ttm)
1.48B
Revenue Growth
+7.94%
P/S Ratio
2.04
Revenue / Employee
22.80M
Employees
65
Market Cap
3.03B
Revenue by Segment
Fiscal year ended Jun 30, 2025 See the full TYO:6090 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.42B | -34.00M | -2.34% |
| Jun 30, 2025 | 1.46B | 110.00M | 8.18% |
| Jun 30, 2024 | 1.35B | 46.00M | 3.54% |
| Jun 30, 2023 | 1.30B | 76.00M | 6.21% |
| Jun 30, 2022 | 1.22B | 99.00M | 8.81% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| MEDINET | 998.00M |
| PRISM BioLab Co.,LTD | 737.27M |
| SUSMED,Inc. | 679.00M |
| Kringle Pharma | 342.21M |
| D. Western Therapeutics Institute | 247.00M |
| Ribomic | 7.50M |